The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease

Author(s): Natasha B. Hunter, MD¹; Heather A. Parsons, MD^1,2; Leslie Cope, PhD³; Jenna V. Canzoniero, MD, MS³; Fabio C.P. Navarro, PhD⁴; Sherif El-Refai, PharmD, PhD⁴; Jesus D. Anampa, MD, MS⁵; Joseph A. Sparano, MD⁵; Mothaffar Rimawi, MD⁶; Anna Maria Storniolo, MD⁷; Candace Mainor, MD⁸; Rita Nanda, MD⁹; Angela DeMichele, MD, MSCE¹⁰; Gaorav P. Gupta, MD, PhD¹¹; Erica J. Stringer-Reasor, MD¹²; Filipa Lynce, MD^2,8; Erin F. Cobain, MD¹³; Shannon Puhalla, MD¹⁴; Rachel Jankowitz, MD^10,14; Brent Rexer, MD, PhD¹⁵; Ingrid Mayer, MD, , MSCI¹⁵; E. Shelley Hwang, MD, MPH, MBA¹⁶; Kimberly Blackwell, MD¹⁶; Walid El Ayass, MD¹⁷; Young Lee, MD¹⁸; Carol Tweed, MD¹⁸; Mary Wilkinson, MD^3,19; Angela Pennisi, MD¹⁹; Bonnie Sun, MD³; Pamela Wright, MD³; Julie R. Gralow, MD¹; Richard Chen, MD⁴; Sean M. Boyle, PhD⁴; Vered Stearns, MD³; Antonio C. Wolff, MD³; Ben Ho Park, MD, PhD¹⁵;

Source: DOI: 10.1200/JCO-25-02934

Dr. Anjan Patel's Thoughts

Primary objective not met, ctDNA clearance post- neoadjuvant therapy (NAT) cannot reliably predict pathologic complete response (pCR) and shouldn't be used to defer surgery. But the prognostic data are striking: post-NAT ctDNA positivity independently predicted recurrence in triple-negative breast cancer (TNBC) (HR 8.9), and the postsurgical landmark analysis is essentially binary, 100% of ctDNA-positive patients recurred while 94% of ctDNA-negative patients were disease-free at 5 years (HR 128). Not practice-changing yet pending prospective utility trials, but this strongly validates ultrasensitive ctDNA as a prognostic tool and a smart enrollment biomarker for future escalation/de-escalation trials.

PURPOSE

Patients with stage II/III human epidermal growth factor receptor 2 (HER2)???positive or triple-negative breast cancer (TNBC) frequently receive neoadjuvant therapy (NAT). Although pathologic complete response (pCR) correlates with improved outcomes, many non-pCR patients have long-term survival. Circulating tumor-DNA (ctDNA) minimal residual disease (MRD) assessment may provide additional or superior risk stratification.

METHODS

Pathologic Response Evaluation and Detection in Circulating Tumor-DNA is a prospective, multicenter study evaluating ctDNA as a biomarker of treatment response using a tumor-informed, ultrasensitive (

RESULTS

Of 227 enrolled patients, 220 were evaluable for pCR (48% HER2-positive; 52% TNBC) and 91 patients (41%) had pCR. The primary objective was not met. Although all patients with pCR were ctDNA-negative after NAT, 40% of non-pCR patients were also ctDNA-negative (NPV, 60% [95% CI, 0.50 to 0.69]). However, the prespecified secondary objective was met. Detectable ctDNA after NAT was prognostic for recurrence (hazard ratio [HR], 8.9 [95% CI, 2.4 to 33]; P = .001), independent of pCR. Additionally, detectable ctDNA after surgery identified patients extremely high recurrence risk (HR, 128 [95% CI, 15 to 1,083]; P < .001), while ctDNA-negative patients after surgery had 94% 5-year IDFS.

CONCLUSION

In HER2-positive breast cancer and TNBC, ctDNA after NAT does not discriminate pCR from non-pCR. However, ctDNA provides markedly superior prognostic stratification, identifying patients with exceptional outcomes and those extreme risk. These findings support ctDNA-guided therapeutic de-escalation and escalation strategies.

Author Affiliations

¹Fred Hutchinson Cancer Center, University of Washington, Seattle, WA; ²Dana Farber Cancer Institute, Boston, MA; ³Johns Hopkins University, Baltimore, MD; ⁴Personalis, Fremont, CA; ⁵Montefiore Einstein Comprehensive Cancer Center, Bronx, NY; ⁶Baylor College of Medicine, Houston, TX; ⁷Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN; ⁸Medstar Georgetown University-Hospital-Lombardi Comprehensive Cancer Center, Washington, DC; ⁹University of Chicago, Chicago, IL; ¹⁰University of Pennsylvania, Philadelphia, PA; ¹¹University of North Carolina, Chapel Hill, NC; ¹²University of Alabama Birmingham, Birmingham, AL; ¹³Rogel Cancer Center, University of Michigan, Ann Arbor, MI; ¹⁴University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA; ¹⁵Vanderbilt University Medical Center, Nashville, TN; ¹⁶Duke University and Duke Cancer Institute, Durham, NC; ¹⁷Tidal Health, Peninsula Regional Medical Center, Salisbury, MD; ¹⁸Anne Arundel Medical Center, Annapolis, MD; ¹⁹Inova Schar Cancer, Fairfax, VA

Low-Dose Tamoxifen in Noninvasive Breast Neoplasia: Long-Term Results From an Individual-Participant Data Pooled Analysis

Among 1,545 women included with a median follow-up of 9.4 years in postmenopausal women, breast cancer events occurred in 40 of 335 receiving low-dose tamoxifen versus 93 of 401 controls HR, 0.51, with a 10-year absolute reduction of 11.2%. Among premenopausal women, no significant reduction was observed dose was 5mg daily of 10mg every other day in ductal carcinoma in situ (DCIS) and high-risk pts. Less is as good.

Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial

644 patients who are triple-negative breast cancer (TNBC) not candidates for immunotherapy were randomly assigned to receive Dato-DXd (n = 323) or chemotherapy (n = 321). Median progression-free survival (PFS) was 10.8 months with Dato-DXd and 5.6 months with chemotherapy. Median overall survival (OS) was 23.7 months and 18.7 months with Dato-DXd and chemotherapy, respectively HR 0.79; P = 0.029]. Treatment-related adverse events (TRAEs) of grade ≥3 were reported in 105 (33%) and 89 (29%) patients who received Dato-DXd and chemotherapy, respectively, they were more treatment discontinuation in the chemotherapy arm secondary to treatment related adverse events in 14 (4%) and 23 (7%) patients. There were no treatment-related deaths in either arm. New standard of care? Recall this is on patients not eligible for immunotherapy.

Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1

Less radiation (40Gy vs 50 Gy) was non inferior in preventing locoregional recurrence and distant mets, also lymphedema rates were not worse. Would love feedback from our rad onc, but it seems less is as good.

HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer

Progression-free survival (PFS) was statistically significantly improved with addition of tucatinib versus placebo 24.9 v 16.3 months regardless of the presence/absence of BM or hormone receptor status.

Role of neoadjuvant versus adjuvant chemotherapy, dose density, and treatment schedule in biologically high-risk HR+/HER2- breast cancer: A pooled analysis of the WSG ADAPT-HR+/HER2- and PlanB trials.

1467 pts with RS > 25 and 551 with clinically (neoadjuvant cohort in ADAPT-HR+/HER2-) or pathologically N2, (longer) docetaxel-based CTx showed better distant, invasive disease-free survival in N2-3 pts patients with RS ≤25, OS was also shown in pts with RS>25 anthracycline regimens did not show a significant survival difference in high-risk HR+/HER2 whether used in neoadjuvant or adjuvant setting. So may be no anthracycline for HR+ve pts who are high risk disease.